Zhao Hongru, Xiao Zheman, Zhang Lei, Ford Janet, Zhong Shiying, Ye Wenyu, Li Jinnan, Tockhorn-Heidenreich Antje, Cotton Sarah, Chen Chunfu
The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Renmin Hospital of Wuhan University, Wuhan, People's Republic of China.
J Pain Res. 2023 Feb 3;16:357-371. doi: 10.2147/JPR.S371887. eCollection 2023.
This study assessed treatment patterns, disease burden, outcomes, and unmet needs among patients with episodic migraine (EM) in China using Adelphi Migraine Disease Specific Programme™ (DSP) real-world data.
Migraine is a prevalent and debilitating neurological disorder which presents a major public health burden globally. Research on characteristics, disease burden, and treatment patterns in EM patients in China is limited.
Data were drawn from an existing data set Adelphi Migraine DSP, a point-in-time survey conducted in China (January-June 2014). Internists/neurologists completed patient record forms for the next 9 patients who consulted them in clinical practice; these same patients completed the 'patient self-completion questionnaires'. Descriptive analyses were used to assess key variables: patient demographics, treatment patterns (current acute and preventive medication [AM/PM]), effectiveness, issues with existing treatment, Migraine Disability Assessment (MIDAS) scores, and Work Productivity and Activity Impairment scores.
Total of 125 internists/neurologists provided data on 1113 patients with EM (headache days/month <15). Mean (standard deviation [SD]) age was 43.8 (13.1) years; mean (SD) number of migraine days/month was 3.2 (1.7). AM was prescribed in 86.1% of patients (non-steroid anti-inflammatory drugs [NSAIDs]: 62.7%; triptans: 7.7%), PM in 38.5%, and both in 24.9% of patients. Approximately 55% of patients experienced ≥1 issue with their current AM or PM. Migraine-related symptoms (including nausea, photophobia, and phonophobia) were fully controlled in <50% of patients receiving NSAIDs (21.7-38.4%) or triptans (32.4-43.5%). Insufficient response to current AM (migraine headache fully resolved within 2 hours in ≤3/5 attacks) was reported by 42.5% of patients. Mild-to-severe disability was reported by 36.8% of patients with a mean (SD) MIDAS score of 5.8 (7.3). Overall, 58.0% of work time was impaired (including time missed and impairment while working).
This analysis suggests, despite existing treatment options, disease burden and unmet medical needs remain substantial in Chinese patients with EM.
本研究使用阿德尔菲偏头痛疾病特定项目™（DSP）的真实世界数据，评估中国发作性偏头痛（EM）患者的治疗模式、疾病负担、治疗结果及未满足的需求。
偏头痛是一种常见且使人衰弱的神经系统疾病，在全球造成重大公共卫生负担。关于中国EM患者的特征、疾病负担及治疗模式的研究有限。
数据来自现有的阿德尔菲偏头痛DSP数据集，这是一项于2014年1月至6月在中国进行的时间点调查。内科医生/神经科医生为其在临床实践中接下来诊治的9例患者填写患者记录表；这些患者同时完成“患者自填问卷”。采用描述性分析评估关键变量：患者人口统计学特征、治疗模式（当前急性和预防性药物[AM/PM]）、疗效、现有治疗存在的问题、偏头痛残疾评估（MIDAS）评分以及工作效率和活动障碍评分。
共有125名内科医生/神经科医生提供了1113例EM患者（每月头痛天数<15天）的数据。平均（标准差[SD]）年龄为43.8（13.1）岁；平均（SD）每月偏头痛天数为3.2（1.7）天。86.1%的患者开具了AM（非甾体抗炎药[NSAIDs]：62.7%；曲坦类药物：7.7%），38.5%的患者开具了PM，24.9%的患者两者都开具了。约55%的患者在当前的AM或PM治疗中出现≥1个问题。在接受NSAIDs（21.7 - 38.4%）或曲坦类药物（32.4 - 43.5%）治疗的患者中，<50%的患者偏头痛相关症状（包括恶心、畏光和畏声）得到完全控制。42.5%的患者报告当前的AM治疗反应不足（≤3/5次发作时偏头痛头痛在2小时内完全缓解）。36.8%的患者报告有轻度至重度残疾，平均（SD）MIDAS评分为5.8（7.3）。总体而言，58.0%的工作时间受到影响（包括缺勤时间和工作时的效率受损）。
该分析表明，尽管有现有的治疗选择，但中国EM患者的疾病负担和未满足的医疗需求仍然很大。
